Lytix Biopharma AS - New share capital registered

Oslo, Norway, 23 December 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 17 December 2024 (the "Announcement") regarding the successful completion of a private placement (the "Private Placement") of new shares raising NOK 100 million in gross proceeds, and a retail offering (the "PrimaryBid Offering") of new shares raising NOK 11.3 million in gross proceeds via the PrimaryBid platform (together with the new shares in the Private Placement, the “Offer Shares”).

The share capital increase relating to the Private Placement and the PrimaryBid Offering has today been registered with the Norwegian Register of Business Enterprises (the "NRBE"). In total 18,549,131 Offer Shares have been issued through the Private Placement and the PrimaryBid Offering. The Company's new share capital is NOK 6,815,943.40, divided into 68,159,434 shares, each with a par value of NOK 0.10.

The Offer Shares are expected to be registered in the Norwegian Central Securities Depository (VPS) today, on 23 December 2024, or on 27 December 2024.

The share capital increase relating to the 102,568 shares to be issued to settle part of the fee to underwriters in the Private Placement, as further described in the Announcement, has not yet been registered with the NRBE.

Disclosure regulation:

This information is subject to a duty of disclosure pursuant to the Company's continuing obligations as a company listed on Euronext Growth Oslo.

For more information, please contact:

Gjest Breistein, CFO

+47 952 60 512

gjest.breistein@lytixbiopharma.com

Lytix in brief:

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.